Avelumab and Merkel Cell Carcinoma: Examining the Biological Plausibility of Causation
From General Health Education to Occupational Exposure Concerns
In the domain of mass production, the legacy of general health and science information has long provided a foundational framework for understanding broad population-level risks and preventive measures. This heritage emphasizes accessible, evidence-based communication about lifestyle factors, environmental exposures, and their potential links to disease. Within this context, discussions of cancer causation have traditionally focused on well-established risk factors such as smoking, diet, and occupational hazards in heavy industries. However, as therapeutic landscapes evolve, particularly with the increasing use of immunomodulatory agents in clinical settings, a new dimension of exposure concern emerges. The transition from general health education to a more specialized occupational exposure perspective requires careful consideration of how biological agents used in treatment may intersect with workplace safety. Specifically, the administration of monoclonal antibodies like avelumab in healthcare or research environments introduces a novel variable: potential unintended exposure among workers handling these substances. While the primary focus remains on patient outcomes, the possibility of occupational exposure to such agents raises questions about long-term risk profiles, including any theoretical association with malignancies like Merkel cell carcinoma. This pivot from general health literacy to a targeted occupational health lens underscores the need for updated risk assessment frameworks in mass production settings where biologic therapies are manufactured or administered.
Bridging to Avelumab's Mechanism and Clinical Use
Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the biological plausibility of avelumab causing or contributing to Merkel cell carcinoma requires careful examination of the drug's mechanism, reported adverse effects, and the natural history of the disease.
Etiology of Merkel Cell Carcinoma and Avelumab's Role
Merkel cell carcinoma has two primary etiologies: approximately 80% of cases are caused by the Merkel cell polyomavirus, while the remaining 20% are induced by ultraviolet light exposure leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment for metastatic MCC involves anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer duration of responses compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385/). Despite these benefits, approximately 50% of patients do not respond to treatment or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). The question of causation—whether avelumab can induce Merkel cell carcinoma—is distinct from its therapeutic use. Avelumab is designed to block PD-L1, thereby enhancing the immune system's ability to attack cancer cells. This mechanism is not known to initiate oncogenesis; rather, it aims to treat existing malignancies.
Evidence on Adverse Effects and Causation
The reported adverse effects of avelumab include immune-related events such as hypercalcaemia due to reactivation of sarcoidosis, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). No evidence in the provided sources suggests that avelumab directly causes Merkel cell carcinoma. Instead, the drug is used to treat the disease, and some patients may become refractory to it, requiring alternative therapies such as combined ipilimumab and nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). Regarding the timeline between exposure and documented harm, the provided evidence does not describe cases where avelumab administration preceded the development of Merkel cell carcinoma. In clinical practice, avelumab is administered to patients already diagnosed with metastatic MCC. The JAVELIN Merkel 200 trial evaluated avelumab in patients with chemotherapy-refractory disease, and responses were observed over weeks to months (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune-related adverse events can occur during treatment, but these are distinct from the primary malignancy. For example, one case report described hypercalcaemia due to sarcoidosis reactivation during avelumab therapy, which resolved with corticosteroids, and avelumab was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This indicates that while irAEs can occur, they do not represent new primary cancers.
Risk Context and Conclusion
Risk anchors for affected patients include the adequacy of warnings regarding avelumab and Merkel cell carcinoma. The prescribing information for avelumab includes warnings about immune-mediated adverse reactions, but the provided evidence does not indicate that the drug carries a warning for causing MCC. Given that avelumab is approved specifically for treating metastatic MCC, the risk of it causing the same disease is biologically implausible based on current understanding. Causation-related considerations would require evidence of avelumab initiating MCC in a patient without pre-existing disease, which is not supported by the available data. The timeline between exposure and harm is relevant only in the context of treatment failure or progression of existing MCC, not de novo causation. In summary, the biological plausibility of avelumab causing Merkel cell carcinoma is not supported by the provided evidence. Avelumab is an effective treatment for MCC, and its mechanism of action as a PD-L1 inhibitor does not involve oncogenic pathways. The reported adverse effects are immune-related and do not include induction of MCC. For patients, the primary risk is lack of response or development of irAEs, not causation of the disease itself.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Can avelumab cause Merkel cell carcinoma?
No, based on current evidence, avelumab is not known to cause Merkel cell carcinoma. It is used to treat metastatic MCC, and its mechanism as a PD-L1 inhibitor does not involve oncogenic pathways. The drug's adverse effects are immune-related and do not include induction of MCC.
What is the biological plausibility of avelumab causing MCC?
The biological plausibility is not supported. Avelumab enhances the immune system to attack cancer cells and is not known to initiate oncogenesis. MCC is primarily caused by Merkel cell polyomavirus or UV-induced mutations, and avelumab is used therapeutically for existing disease.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
- Avelumab approval and mechanism (PubMed)
- MCC etiology (PubMed)
- Avelumab adverse effects - sarcoidosis (PubMed)
- Refractory MCC treatment (PubMed)
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.